Takeda and Halozyme sign global agreement for Enhanze technology
Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter’s Enhanze drug…
All articles by Salong Debbarma
Salong Debbarma
-
-
Santhera grants Agamree rights to Nxera for DMD
Santhera Pharmaceuticals has entered an exclusive licensing agreement with Nxera Pharma for Agamree (Vamorolone) to treat Duchenne muscular dystrophy (DMD)…
-
Octapharma receives FDA approval for new Fibryga formulation in AFD
Octapharma has received approval from the US Food and Drug Administration (FDA) for a new 2-gram (g) formulation of Fibryga…
-
Day One concludes Mersana Therapeutics acquisition
Day One Biopharmaceuticals has concluded its acquisition of Mersana Therapeutics after meeting all the tender offer conditions. The tender offer…
-
Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
Cellenkos has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational CK0804 regulatory T…
-
Zai Lab’s Augtyro receives NMPA approval for solid tumours in China
Zai Lab has received approval from China’s National Medical Products Administration (NMPA) for the supplemental new drug application (sNDA) for…
-
Takeda and Protagonist seek FDA approval for rusfertide to treat PV
Takeda and Protagonist Therapeutics have jointly submitted a new drug application (NDA) seeking approval from the US Food and Drug…
-
Arrowhead receives Health Canada authorisation for Redemplo to treat FCS
Arrowhead Pharmaceuticals has received authorisation from Health Canada for its small interfering RNA (siRNA) medicine, Redemplo (plozasiran), as an adjunct…
-
Insilico and Servier announce $888m oncology research agreement
Insilico Medicine has entered a multi-year research and development (R&D) collaboration with Servier, worth up to $888m, to develop and…
-
Samsung Bioepis initiates Byooviz commercialisation in Europe
Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in Europe. The company has assumed…